Company: CERO
Filing Date: 2025-07-21
Form Type: S-1
Source: 0001213900-25-066152
Chunk: 398

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-07-21
Form: S-1
Chunk 398
---
 deliver any shares of Common Stock issuable upon exercise. If at the time of exercise of the January 2025 Common Warrants, there is no effective registration statement registering the shares of the Common Stock underlying the January 2025 Common Warrants, such warrants may be exercised on a cashless basis pursuant to their terms During the period from January 1, 2025 to April 10, 2025, 1,098shares of Series A Preferred Stock were converted into 14,442shares of Common Stock. The conversion ratio was based on the Series A Certificate of Designations and reflected the applicable Alternate Conversion Price. During the period from January 1, 2025 to April 10, 2025, 75shares of Series B Preferred Stock were converted into 2,500shares of Common Stock. The conversion ratio was based on the Series B Certificate of Designations and reflected the applicable Alternate Conversion Price. F-61 During the period from January 1, 2025 to April 10, 2025, the Company sold 14,531shares of Common Stock of the Company pursuant to the New Keystone Purchase Agreement for net proceeds of $ 1,227,242. On February 5, 2025, the Company announced the pricing of a reasonable best efforts public offering (the “Offering”), with participation from a member of the Company’s board of directors and a single institutional investor, for the purchase and sale of (i) 127,551shares of its common stock, par value $ 0.0001per share (the “Common Stock”) or common stock equivalents in lieu thereof; and (ii) common warrants to purchase up to 127,551shares of common stock (the “Warrants”), at a combined public offering price of $ 39.20per share and Warrant. In connection with the Offering, on February 5, 2025, the Company entered into a securities purchase agreement (the “SPA”) with the investors. The SPA contains customary representations, warranties and agreements of the Company and each investor and customary indemnification rights and obligations of the parties. In connection with this offering, the Company received net proceeds of approximately $ 4.5million. From January 1, 2025 to April 11, 2025, the Company issued 116,764shares of its common stock of the aggregate amount of shares of 127,551shares sold. The remaining 10,787common shares are issuable. The Warrants have an